secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anteris Technologies Global Corp. (AVR)
CIK:        0002011514
Form:       8-K
Filed at:   2025-03-21T23:59:59+00:00
Accession:  0001140361-25-009748
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anteris DurAVR THV reports zero PPM at one year in small annuli patients
------------------------------------------------------------------------

- One-year hemodynamic data: EOA 2.1±0.2 cm², mean gradient 8.6±2.6 mmHg, DVI 0.58 (n=65).
- Zero prosthesis-patient mismatch (PPM) in small annuli patients; commercial valves report 11-35% PPM.
- No valve or cardiovascular related mortality at one year; consistent safety profile.
- Data to support planned IDE submission to FDA for DurAVR THV pivotal study.
- Results presented at Sydney Valves late-breaking clinical trial session on March 21, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2011514/000114036125009748/0001140361-25-009748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2011514/000114036125009748/ef20045825_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-009748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer